A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Inclusion Criteria:

* Non smokers or light smokers and willing to limit smoking for the period of confinement to 4 cigarettes per day
* Body Mass Index of 18-35 kg/m2
* Negative test for breathalyzer alcohol and drugs of abuse and HIV antibody test at Screening
* Agrees to protocol-defined use of effective contraception
* Participants with Mild or Moderate Hepatic Impairment
* Must have mild or moderate hepatic impairment
* On a stable dose of medication and/or treatment regimen for at least 2 weeks before dosing as well as during the study
* Clinical laboratory evaluations within the reference range for the test laboratory
* Participants with normal hepatic function have no clinically significant findings from medical history, physical examination, Laboratory values within protocol defined parameters

Exclusion Criteria:

* Any other investigational study drug trial within 5 half-lives of that investigational study drug or 30 days prior to dosing with Abiraterone acetate, whichever is longer
* Inability to swallow four (4) 250 mg abiraterone acetate tablets
* History of or current clinically significant medical illness that would potentially alter absorption and/or excretion of orally administered drugs
* History or presence of a clinically significant abnormal ECG
* Donation of blood or significant loss of blood within 56 days prior to Day 1 or planned donation of blood or plasma from Screening through 30 days after Day 1
* Use of any prescription medications/products or any OTC, non-prescription unrelated to existing allowable stable medical conditions within 5 half-lives of that product or 7 days prior to dosing with abiraterone acetate, whichever is longer
* Clinically significant renal laboratory findings
* Participants with Mild or Moderate Hepatic Impairment will be excluded - any significant medical history other than hepatic impairment that may affect the interpretation of the data or which otherwise contraindicates participation in the study
* Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within 2 weeks
* Autoimmune liver disease; Esophageal variceal bleeding within 6 months prior to Screening, unless successfully treated with banding, Gastric varices
* Spontaneous bacterial peritonitis within 3 months prior to Screening
* Portosystemic shunt, Organ transplant, Wilson's disease, Cholestatic liver disease (e g , primary biliary cirrhosis or primary sclerosing cholangitis)
* Clinically significant laboratory findings except as related to hepatic impairment
* Control Participants with Normal Hepatic Function Any significant laboratory results, including specifically Positive for Hepatitis B or C, Hemoglobin \< 12 0 g/dL LFTs outside of normal limits